Phase Ib/II trial of envafolimab, a novel subcutaneous singledomain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors

被引：0
|
作者：
Liu, T. [1 ]
Feng, Y. [1 ]
Xu, X. [1 ]
Ren, X. [2 ]
Jia, J. [3 ]
Pan, H. [4 ]
Wang, B. [5 ]
Wu, B. [6 ]
Cao, X. [7 ]
Liu, J. [8 ]
Yang, Y. [9 ]
Xiao, S. [10 ]
Qin, L. [10 ]
Zhu, D. [10 ]
Xu, S. [10 ]
Huang, W. [10 ]
机构：
[1] Fudan Univ, Zhongshan Hosp, Dept Oncol, Shanghai, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Dept Biol Therapy, Tianjin, Peoples R China
[3] Dongguan Peoples Hosp, Dept Oncol, Dongguan, Peoples R China
[4] Zhejiang Univ, Sir Run Run Shaw Hosp, Dept Med Oncol, Sch Med, Hangzhou, Peoples R China
[5] 960th Hosp PLA Joint Logist Support Force, Dept Oncol, Jinan, Peoples R China
[6] China Med Univ, Shengjing Hosp, Dept Urol, Shenyang, Peoples R China
[7] Shanxi Med Univ, Hosp 1, Dept Urol, Taiyuan, Peoples R China
[8] Dalian Med Univ, Affiliated Hosp 1, Dept Med Oncol, Dalian, Peoples R China
[9] Kunming Med Univ, Yunnan Canc Hosp, Affiliated Hosp 3, Dept Urol, Kunming, Peoples R China
[10] 3D Med Inc, Dept Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2188
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1049P
引用
收藏
页码：S635 / S635
页数：1
相关论文
共 50 条
  • [1] Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
    Toshio Shimizu
    Takako Eguchi Nakajima
    Noboru Yamamoto
    Kan Yonemori
    Takafumi Koyama
    Shunsuke Kondo
    Yu Sunakawa
    Naoki Izawa
    Yoshiki Horie
    Silong Xiang
    Siying Xu
    Lan Qin
    John Gong
    David Liu
    Investigational New Drugs, 2022, 40 : 1021 - 1031
  • [2] Phase I study of envafolimab (KN035), a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors
    Shimizu, Toshio
    Nakajima, Takako Eguchi
    Yamamoto, Noboru
    Yonemori, Kan
    Koyama, Takafumi
    Kondo, Shunsuke
    Sunakawa, Yu
    Izawa, Naoki
    Horie, Yoshiki
    Xiang, Silong
    Xu, Siying
    Qin, Lan
    Gong, John
    Liu, David
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1021 - 1031
  • [3] First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors
    Papadopoulos, Kyriakos P.
    Harb, Wael
    Peer, Cody J.
    Hua, Qiong
    Xu, Siying
    Lu, Haolan
    Lu, Ni
    He, Yue
    Xu, Ting
    Dong, Ruiping
    Gong, John
    Liu, David
    ONCOLOGIST, 2021, 26 (09): : E1514 - E1525
  • [4] A phase Ia/Ib trial of the anti-PD-L1 human monoclonal antibody (mAb), CS1001, in patients (pts) with advanced solid tumors or lymphomas.
    Shen, Lin
    Cao, Junning
    Li, Jin
    Pan, Hongming
    Xu, Nong
    Zhang, Yan
    Wang, Jingru
    Wang, Yin
    Dai, Hangjun
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] A phase 1 study of IMC-001, novel anti-PD-L1 antibody, in patients with advanced solid tumors
    Keam, Bhumsuk
    Kim, Tae Min
    Oh, Do-Youn
    Ock, Chan-Young
    Kang, Won Ki
    Park, Yeon Hee
    Lee, Jeeyun
    Lee, Ji Hye
    Song, Yun Jeong
    Park, Young Suk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [6] JAVELIN PARP medley: A phase Ib/II study of avelumab (anti-PD-L1) plus talazoparib in locally advanced or metastatic solid tumors
    Yap, T. A.
    Beck, J. T.
    Stewart, R. A.
    Dahm, S. C.
    Chappey, C.
    Cesari, R.
    Scheuber, A.
    Galsky, M. D.
    Wise, D.
    ANNALS OF ONCOLOGY, 2018, 29 : 441 - 441
  • [7] Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
    Taylor, Matthew H.
    Lee, Chung-Han
    Makker, Vicky
    Rasco, Drew
    Dutcus, Corina E.
    Wu, Jane
    Stepan, Daniel E.
    Shumaker, Robert C.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (11) : 1154 - +
  • [8] Phase I study of anti-PD-L1 antibody MPDL3280A in patients with advanced solid tumors
    Murakami, Haruyasu
    Yamamoto, Noboru
    Kenmotsu, Hirotsugu
    Takahashi, Toshiaki
    Fujiwara, Yutaka
    Mizugaki, Hidenori
    Ishida, Yoshimasa
    Kawakami, Tomohisa
    ANNALS OF ONCOLOGY, 2015, 26 : 98 - 98
  • [9] Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial
    Patnaik, Amita
    Yap, Timothy A.
    Chung, Hyun Cheol
    de Miguel, Maria J.
    Bang, Yung-Jue
    Lin, Chia-Chi
    Su, Wu-Chou
    Italiano, Antoine
    Chow, Kay Hoong
    Szpurka, Anna M.
    Yu, Danni
    Zhao, Yumin
    Carlsen, Michelle
    Schmidt, Shelly
    Vangerow, Burkhard
    Gandhi, Leena
    Xu, Xiaojian
    Bendell, Johanna
    CLINICAL CANCER RESEARCH, 2021, 27 (05) : 1267 - 1277
  • [10] Avelumab (MSB0010718C), an Anti-PD-L1 Antibody, Evaluated in a Phase Ib Trial in Patients with Advanced Mesothelioma
    Thomas, Anish
    Hassan, Raffit
    Patel, Manish
    Nemunaitis, John
    Bennouna, Jaafar
    Powderly, John
    Taylor, Matthew H.
    Bajars, Marcis
    Von Heydebreck, Anja
    Gulley, James L.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S748 - S748
12345